Transaction #1520 · Form 4 · 0001021771-25-000140
BioRestorative Therapies, Inc. · Stock award · Common Stock
BioRestorative Therapies, Inc. · Transacted October 6, 2025 · Filed October 20, 2025
What does this filing report?
An SEC Form 4 filing for BioRestorative Therapies, Inc. records a stock award involving Common Stock on October 6, 2025. The reported quantity was 15,625. The filing date is October 20, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001505497
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 15,625
- Reported price
- 1.6
- Reference value
- 25,000
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 187,497
- Ownership description
- Not reported
- SEC acceptance time
- Oct 20, 2025, 8:02 AM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- ALSTODT LANCE ↗
President, CEO, COB · Director · 10% owner
CIK 0001756228
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The option is currently exercisable.
- F2
- The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
- F3
- The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
- F4
- The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.